In the present study, we retrospectively analysed the results of HSCT in 47 consecutive patients with MDS diagnosed at our department between 2002 and 2019, with a focus on possible predictive factors influencing overall survival (OS), the development of relapse, infections, and the occurrence of graft versus host disease (GvHD). In a univariate analysis, the pre-transplantation value of blasts in the marrow < 5% (p = 0.006), the revised International Prognostic Scoring System (IPSS-R) (p = 0.041), and karyotype (p = 0.009) were predictive of OS. Neither the elevation of serum ferritin (> 1000 ug/ml) nor increased C-reactive protein (CRP) (> 5 mg/l) was associated with shorter OS. In contrast, elevated serum lactate dehydrogenase (LDH) (> 213 U/l) was associated with shorter OS (p = 0.04).

4th Department of Internal Medicine Haematology University Hospital and Charles University Hradec Kralove Czech Republic

Leuk Res Rep. 2022 Apr 06;17:100309. doi: 10.1016/j.lrr.2022.100309. PubMed

Zobrazit více v PubMed

Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096–1107. doi: 10.1182/blood-2018-10-844696. PubMed DOI

de Witte T., Bowen D., Robin M., Malcovati L., Niederwieser D., Yakoub-Agha I I. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–1762. doi: 10.1182/blood-2016-06-724500. PubMed DOI PMC

Bejar R., Stevenson K.E., Caughey B., Coleman R.L., Mar B.G., Stojanov P. Somatic mutations predict poor outcome in atients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J. Clin. Oncol. 2014;32(25):2691–2698. doi: 10.1200/JCO.2013.52.3381. PubMed DOI PMC

Kebriaei P., Kline J., Stock W., Kasza K., Le Beau M.M., Larson R.A., van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005;35(10):965–970. doi: 10.1038/sj.bmt.1704938. PubMed DOI

Warlick E.D., Cioc A., Defor T., Dolan M., Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol. Blood Marrow Transplant. 2009;15(1):30–38. doi: 10.1016/j.bbmt.2008.10.012. PubMed DOI

Onida F F., Brand R., van Biezen A., Schaap M M., von dem Borne PA P.A., Maertens J. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for blood and marrow transplantation-chronic malignancies working party. Haematologica. 2014;99(10):1582–1590. doi: 10.3324/haematol.2014.106880. PubMed DOI PMC

Nevill T.J., Fung H.C., Shepherd J.D., Horsman D.E., Nanteet S.H., Klingemann H.G. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92(6):1910–1917. doi: 10.1182/blood.V92.6.1910. PubMed DOI

Sorror M.L., Sandmaier B.M., Storer B.E., Maris Michael B, Baron Frédéric. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 2007;25(27):4246–4254. doi: 10.1200/JCO.2006.09.7865. PubMed DOI

Wimazal F., Sperr W.R., Kundi M., Vales A., Fonatsch C., Thalhammer-Scherrer R R. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann. Oncol. 2008;19(5):970–976. doi: 10.1093/annonc/mdm595. PubMed DOI

Wimazal F., Sperr W.R., Kundi M., Meidlinger P., Fonatsch C., Jordan J.H. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk. Res. 2001;25(4):287–294. doi: 10.1016/s0145-2126(00)00140-5. PubMed DOI

Artz A.S., Wickrema A., Dinner S., Godley L.A., Kocherginsky M M., Odenike O. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2008;14(11):1209–1216. doi: 10.1016/j.bbmt.2008.08.004. PubMed DOI PMC

Artz A.S., Logan B., Zhu X., Akpek G., Bufarull R.M., Gupta V. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016;101(11):1426–1433. doi: 10.3324/haematol.2016.145847. PubMed DOI PMC

Armand P., Kim H.T., Virtanen J.M., Parkkola R.L., Itälä-Remes M.A., Majhail N.S. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta- analysis. Biol. Blood Marrow Transplant. 2014;20(8):1248–1251. doi: 10.1016/j.bbmt.2014.04.024. PubMed DOI PMC

Cremers E.M., van Biezen A., de Wreede L.C., Scholten M., Vitek A., Finke J. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. Ann. Hematol. 2016;95(12):1971–1978. doi: 10.1007/s00277-016-2802-z. PubMed DOI PMC

Prem S., Atenafu E.G., Lam W., Law A., Michelis F.V., Kim D. Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. Eur. J. Haematol. 2020;104(2):116–124. doi: 10.1111/ejh.13353. PubMed DOI